Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Research Area(s) / Expertise: Job title: Professor of Medicine and Director of Cardiomyopathy Program
DrLynne Stevenson is aProfessor of Medicine and Director of Cardiomyopathy Program atVanderbilt University Medical Center, Nashville, US. Herresearch experience includes acute and ambulatory hemodynamic monitoring, exercise physiology, heart failure hospitalisations and the interface of arrhythmias and sudden death risk with left ventricular dysfunction. View more
‘Residual Congestion’ in HF
Author(s): Aleksandra Gasecka , Aleksander Siniarski Added: 1 year ago

Imaging & Diagnostics

Heart Failure
HFSA 25: The INTEGRA-D Trial
Author(s): Nir Uriel Added: 7 months ago
HFSA 25 - CCM-D was associated with successful defibrillation and symptom improvement in patients with HFrEF at 6 months in the INTEGRA-D Trial.Dr Nir Uriel (NewYork-Presbyterian, Columbia University Irving Medical Center, US) joins us to discuss findings from the Integra-D trial, evaluating a novel implantable device that provides both cardiac contractility modulation and defibrillation… View more

Heart Failure
Rod S Passman
Research Area(s) / Expertise:

Electrophysiology & Arrhythmia

Atrial Fibrillation

Stroke

Heart Failure Devices

 Job title: Director, Center for Arrhythmia Research Jules J. Reingold Professor of Electrophysiology Professor of Medicine (Cardiology) and Preventive Medicine
Dr Rod SPassman is a cardiac electrophysiologist, a clinician specializing in heart rhythm disorders. He joined Feinberg School of Medicine in 1998 as an assistant professor of Medicine in the Division of Cardiologyand was awarded the title of full professor in 2013. He also holds an appointment in the Department of Preventive Medicine.Dr Passman's main interests arecardiac monitoring and stroke… View more
Research Area(s) / Expertise: Job title: Director
Dr Dan Burkhoff is currently the Director of Heart Failure, Hemodynamics and MCS Research at Cardiovascular Research Foundation, New York, US.Dr Burkhoff's interest include cardiovascular modeling and ventricular mechanics, cardiovascular monitoring, heart failure, device and pharmacologic treatments for heart failure, including left ventricular assist devices.He is also author of Harvi, an… View more
Job title: Professor of Medicine
Omron logo
Omron Healthcare is a manufacturer of medical equipment for therapy and health monitoring. Our range of products includes blood pressure monitors, portable ECG, augmentation index device, respiratory therapy devices, electronic fever thermometers and body fat monitors among others. Our eco-friendly products are not only known for their high quality and performance standards, but also for their… View more
HFSA 25: Sex-Specific Outcomes of Tirzepatide in Obesity-Related HFpEF
Author(s): Barry Borlaug Added: 7 months ago
HFSA 25 - Sex-specific outcomes of tirzepatide in obesity-related HFpEF showed that at baseline, women with HFpEF had more severe heart failure symptoms.Dr Barry Borlaug (Mayo Clinic, US) joins us to discuss a prespecified secondary analysis from the SUMMIT trial, examining sex-specific effects of tirzepatide in patients with heart failure with preserved ejection fraction and obesity.The SUMMIT… View more

Cardiovascular Kidney Metabolic

Heart Failure
AHA 24: The REMS Program for Mavacamten
Author(s): Milind Y Desai Added: 1 year ago
AHA Conference 2024 - 22 month data from the risk evaluation and mitigation strategy (REMS) program for mavacamten (Camzyos; Bristol-Myers Squibb Company) in hypertrophic cardiomyopathy (HCM) patients.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from the REMS program for mavacamten.The REMS program investigated the safety and efficacy of… View more

Heart Failure
THT 25: The RELIEVE-HF Study
Author(s): Gregg Stone Added: 1 year ago
THT Conference 2025 - Outcomes after heart failure patients were treated with an interatrial shunt show heart failure with reduced ejection fraction (HFrEF) patients had further benefit compared to heart failure with preserved ejection fraction (HFpEF) patients. The study's prediction model revealed four independent predictors of two-year adverse outcomes in HFrEF patients treated with medical… View more

Heart Failure